Overview

Doxercalciferol in Recurrent Pediatric Solid Tumors

Status:
Terminated
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of doxercalciferol that can be given to pediatric patients with relapsed solid tumors. The safety of this drug will also be studied. Another goal is to measure the effect of the study drug on the blood levels of calcium and vitamin D.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Treatments:
1 alpha-hydroxyergocalciferol
Ergocalciferols